Human medicines European public assessment report (EPAR): Bonviva, ibandronic acid, Osteoporosis, Postmenopausal, Date of authorisation: 23/02/2004, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Bonviva, ibandronic acid, Osteoporosis, Postmenopausal, Date of authorisation: 23/02/2004, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Bonviva, ibandronic acid, Osteoporosis, Postmenopausal, Date of authorisation: 23/02/2004, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Bonviva, ibandronic acid, Osteoporosis, Postmenopausal, Date of authorisation: 23/02/2004, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Endo

Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Endometrial Neoplasms, Date of authorisation: 17/0

Wil je het laatste nieuws in jouw mailbox? Meld je dan aan voor de nieuwsbrief.